Core Insights - The company is positioned as the only diagnostic imaging firm with a comprehensive portfolio of contrast media and radiopharmaceuticals, leveraging a D3 strategy that integrates smart devices and drugs with digital AI and cloud technology to enhance diagnostic accuracy and therapy delivery [1] - The company reported a strong vitality rate of 55% for new products, indicating that a significant portion of revenue is derived from recent innovations, which is a positive sign for customer satisfaction and market relevance [1] - Financial performance in 2025 exceeded expectations, with organic revenue growth of 3.5% and a record backlog of $21.8 billion, reflecting robust demand in the US and EMEA markets [13][15] Strategic Developments - The acquisition of IntelliRed is expected to generate approximately $270 million in revenue, growing in the low double digits, and will enhance the company's cloud-first imaging ecosystem [2][3] - The company has secured multiple large agreements, including a seven-year partnership with the University of Rochester Medical Center, which will advance diagnostics and precision medicine [3] - The Heartbeat business system is being implemented to improve operational efficiency and customer experience, contributing to margin expansion and productivity [10][12] Product and Market Performance - The company has seen strong performance in pharmaceutical diagnostics, with double-digit organic revenue growth, and mid-single-digit growth in imaging and advanced visualization solutions [4][18] - New product launches, such as the VividPioneer cardiovascular ultrasound system, are contributing to revenue growth and strengthening the company's market position [5][19] - The service business grew mid-single digits, supported by a growing installed base and the introduction of advanced products, which are expected to increase service agreement capture rates [8][60] Financial Metrics - In the fourth quarter, the company reported revenue of $5.7 billion, with product revenue growing 7.9% and service revenue increasing 5.5% [13] - Adjusted EPS for the fourth quarter was $1.44, reflecting a slight decline due to tariff impacts, but showing an 11% growth when excluding these effects [14] - For 2026, the company anticipates organic revenue growth of 3% to 4%, with adjusted EBIT margins expected to expand by 50 to 80 basis points [23][24] Future Outlook - The company is optimistic about the potential for additional margin expansion and revenue growth driven by new product introductions and strategic acquisitions [27][56] - The capital equipment environment remains healthy, with a positive outlook for investment in diagnostic imaging technologies, particularly in the US and European markets [75][78] - The company is taking a cautious approach to the Chinese market, anticipating a decline in 2026 but remaining open to potential upside as market conditions evolve [38][39]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $5.7 billion, representing a 4.8% organic growth year-over-year, exceeding expectations [13] - For the full year 2025, total revenue reached $20.6 billion, with organic growth of 3.5%, ahead of guidance [15] - Adjusted EBIT margin for Q4 was 16.7%, down 200 basis points due to tariff expenses and unfavorable mix [13] - Adjusted EPS for Q4 was $1.44, down 0.7%, but grew 11% when excluding tariff impacts [14] - Free cash flow for Q4 was $916 million, up $105 million year-over-year [15] Business Line Data and Key Metrics Changes - Pharmaceutical Diagnostics saw organic sales growth of 12.7%, driven by global growth in contrast media and pricing execution [19] - Imaging organic revenue grew 5.3% in Q4, with strong performance in EMEA and the US, particularly in nuclear medicine [17] - Advanced Visualization Solutions reported a 4.2% organic revenue increase, supported by new product adoption [18] - Patient Care Solutions experienced a 1.1% decline in organic revenue due to a drop in life support solutions, but EBIT margin improved sequentially [19] Market Data and Key Metrics Changes - Demand in the U.S. and EMEA remained strong, with a record backlog of $21.8 billion, up $2 billion year-over-year [13] - The company secured multiple large agreements, including a significant collaboration with the University of Rochester Medical Center [4] - The capital equipment environment in the U.S. is robust, with many customers planning to increase investments in 2026 [3] Company Strategy and Development Direction - The company is focused on an innovation renaissance, emphasizing integrated solutions for complex and chronic diseases [3] - The strategic framework includes precision care, growth acceleration, and business optimization, with a strong emphasis on the Heartbeat business system to drive productivity and customer experience [10][11] - The planned acquisition of Intelerad is expected to enhance the company's cloud-first imaging ecosystem and drive recurring revenue [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering over $500 million in Flyrcado revenue by year-end 2028, with a long-term billion-dollar opportunity [9] - The outlook for 2026 includes organic revenue growth of 3%-4%, with a cautious approach to the Chinese market [22] - Management anticipates a decline in China for 2026 but sees potential upside if conditions improve [41] Other Important Information - The company deployed over $1.7 billion in innovation investment in 2025, prioritizing programs that strengthen competitiveness [17] - The service business grew mid-single digits in 2025, with expectations for increased capture rates of service agreements due to new product launches [10] Q&A Session Summary Question: Can you provide more color on the 2% order growth and outlook for orders in 2026? - Management noted a robust order backdrop with a book-to-bill ratio of 1.06 times and a record backlog, indicating a positive setup for 2026 [27][28] Question: What is the current state of Flyrcado and its adoption? - Management reported positive feedback from clinicians regarding Flyrcado's image quality and convenience, with consistent delivery rates improving [31][32] Question: How does the company view the situation in China and its impact on EPS? - Management took a cautious approach regarding China, anticipating a decline in 2026 but monitoring for potential upside as conditions evolve [40][41] Question: Can you elaborate on the assumptions for 2026 EPS guidance? - Management explained that the guidance reflects expected volume growth and cost initiatives, with a focus on maintaining investments in growth [44][48] Question: What is the status of the Intelerad acquisition? - The acquisition is expected to close in the first half of the year, enhancing the company's capabilities in cloud-enabled AI solutions [79][80]

There are opportunities. What. What have you been maybe buying in this, you know, recent pullback.You interests that you're in the hyperscale. Look at Oracle, the sell off here. Look at Meta.I mean, these are golden buying opportunities for the next two, three, four years. And that's that's my view where we are in the revolution, that you use these as opportunities. Now, I'd head for the elevators.So I guess the question that I have, Dan, if this is a buying opportunity, what happens if there's another 10% ...